Longevity research peptides

Longevity research peptides span multiple convergent mechanisms addressing the cellular-ageing phenotype: mitochondrial dysfunction (SS-31/elamipretide directly stabilises cardiolipin; humanin and MOTS-c are mitochondrial-derived peptides), telomerase and replicative senescence (epitalon), senolytic clearance of senescent cells (FOXO4-DRI), and the foundational longevity-gene product Klotho whose loss produces dramatic accelerated aging in mice.

The longevity peptide research space is organised around several convergent mechanisms addressing distinct aspects of the cellular-ageing phenotype. Mitochondrial dysfunction — reduced cristae organisation, cardiolipin peroxidation, decreased oxidative phosphorylation efficiency, increased reactive oxygen species leak — is a central feature of aging that connects to cellular senescence, impaired autophagy, and metabolic dysregulation. Telomere shortening drives replicative senescence in dividing cells. Senescent-cell accumulation contributes to age-related tissue dysfunction through the senescence-associated secretory phenotype. Foundational longevity genes like Klotho have loss-of-function phenotypes that dramatically compress lifespan. Contemporary longevity research peptides address one or more of these mechanistic axes. SS-31 (elamipretide, formerly Bendavia, MTP-131) is the leading pharmacological compound targeting mitochondrial dynamics directly. Developed by Hazel Szeto's laboratory at Weill Cornell, the small cell-permeable tetrapeptide (D-Arg-2',6'-dimethyl-Tyr-Lys-Phe-NH₂) selectively partitions into the inner mitochondrial membrane at concentrations ~1000-fold above cytoplasmic levels through its alternating aromatic-cationic architecture. It binds cardiolipin non-covalently, stabilising cristae architecture and preserving respiratory-chain supercomplex organisation during oxidative stress. Stealth BioTherapeutics has advanced the compound through Phase III trials in primary mitochondrial myopathy (MMPOWER-3, negative primary endpoint), Barth syndrome (TAZPOWER, cardiac function improvements), acute STEMI (EMBRACE, negative primary endpoint), and dry AMD (ReCLAIM programme ongoing). Not yet licensed anywhere. Mitochondrial-derived peptides (MDPs) form a mechanistically distinct axis. Humanin is a 24-amino-acid peptide encoded within the mitochondrial 16S rRNA region, discovered by Hashimoto in 2001 as the first MDP with cytoprotective activity against β-amyloid toxicity. Its mechanism involves an FPRL1/gp130/CNTFR/WSX-1 heterotrimeric receptor complex plus direct intracellular Bax/Bak inhibition preventing mitochondrial outer membrane permeabilisation. The S14G analogue (HNG) is ~1000-fold more potent and is the standard research-use variant. MOTS-c is the 16-amino-acid MDP encoded within the mitochondrial 12S rRNA region (discovered by Cohen at USC in 2015), activating AMPK signalling with metabolic-regulatory and exercise-endurance effects (Reynolds et al., Nat Commun 2021). Both are cross-listed in the metabolic cluster given the overlapping insulin-sensitising phenotype. Epitalon (Ala-Glu-Asp-Gly), the Khavinson group's synthetic pineal peptide, engages the telomerase and replicative-senescence axis — reported to upregulate hTERT expression and extend replicative lifespan in cultured human fibroblasts, though the evidence base is largely confined to a single St Petersburg research network and lacks independent Western replication. FOXO4-DRI represents the senolytic strategy — a D-amino-acid retro-inverso peptide developed by Peter de Keizer at Utrecht that selectively kills senescent cells by disrupting the FOXO4-p53 protein-protein interaction on which senescent cells specifically depend. The seminal Baar 2017 Cell publication demonstrated substantial healthspan improvements in aged mice. Klotho is the foundational longevity-gene product — a single-pass transmembrane glycoprotein whose loss-of-function in mice produces dramatic accelerated aging (Kuro-o et al., Nature 1997), overexpression extends mouse lifespan by 20-30% (Kurosu et al., Science 2005), and human centenarians have elevated circulating levels. Standard longevity endpoints include mitochondrial function readouts (Seahorse extracellular flux for OCR/ECAR, high-resolution respirometry, TMRM/JC-1 membrane potential, electron microscopy for cristae structure, cardiolipin lipidomics); cellular-ageing markers (SA-β-galactosidase staining for senescence, SASP cytokines IL-6/IL-8/MCP-1, telomere length by qPCR, hTERT expression, p16INK4a/p21CIP1 immunostaining); aged-rodent functional endpoints (treadmill endurance, cognitive testing, body composition); plasma biomarkers of ageing (circulating humanin, MOTS-c, Klotho, IGF-1 axis, inflammatory panels). None of the longevity peptides is MHRA-licensed in the UK. SS-31 has the deepest clinical-trial safety record through the Stealth Phase III programme but no marketing authorisation. FOXO4-DRI, humanin, and MOTS-c are pre-clinical research chemicals. Klotho protein is available as biochemistry research reagent. None currently sits on the WADA Prohibited List as specifically-named substances (though MOTS-c's exercise-endurance signal in aged mice creates arguable WADA-category applicability). Key research questions include the reason for SS-31's mixed Phase III results across diverse indications, independent replication of Khavinson-group epitalon findings by Western groups, and clinical translation of the compelling mouse Klotho longevity phenotype to human intervention.

Peptides in this category